Register entry
- Registered sites
- 0
- Active NDC listings
- 12
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
1212 active NDC listings: 12 human prescription drug. By marketing category: BLA 11, ANDA 1.
| Dosage form | NDCs |
|---|---|
| injection, solution | 7 |
| injection | 4 |
| tablet, delayed release | 1 |
| Route | NDCs |
|---|---|
| subcutaneous | 10 |
| intravenous | 1 |
| oral | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| nuvaila limited | 12 |
Catalogue
Marketed products
12| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| AMJEVITA | adalimumab-atto | injection, subcutaneous | 84612-399BLA |
| AMJEVITA | adalimumab-atto | injection, subcutaneous | 84612-479BLA |
| AMJEVITA | adalimumab-atto | injection, subcutaneous | 84612-481BLA |
| AMJEVITA | adalimumab-atto | injection, subcutaneous | 84612-482BLA |
| Mesalamine | Mesalamine | tablet, delayed release, oral | 84612-175ANDA |
| WEZLANA | ustekinumab-auub | injection, solution, subcutaneous | 84612-055BLA |
| WEZLANA | ustekinumab-auub | injection, solution, intravenous | 84612-066BLA |
| WEZLANA | ustekinumab-auub | injection, solution, subcutaneous | 84612-076BLA |
| WEZLANA | ustekinumab-auub | injection, solution, subcutaneous | 84612-089BLA |
| WEZLANA | ustekinumab-auub | injection, solution, subcutaneous | 84612-855BLA |
| WEZLANA | ustekinumab-auub | injection, solution, subcutaneous | 84612-876BLA |
| WEZLANA | ustekinumab-auub | injection, solution, subcutaneous | 84612-889BLA |
Enquiry
Common questions
- Is Nuvaila Limited FDA approved?
- Nuvaila Limited holds no registered establishment of its own; 12 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Nuvaila Limited make?
- 12 products are listed under Nuvaila Limited in the openFDA NDC Directory, most often as injection, solution; injection; tablet, delayed release. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.